First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
J. Clin. Oncol 2020 Jun 17;[EPub Ahead of Print], J Vuky, AV Balar, D Castellano, PH O'Donnell, P Grivas, J Bellmunt, T Powles, D Bajorin, NM Hahn, MJ Savage, X Fang, JL Godwin, TL Frenkl, B Homet Moreno, R de Wit, ER PlimackFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.